Adjuvant EGFR-TKIs-based therapy: are we ready?

Documenti analoghi

• EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
  di: Steuer, Conor E., et al.
  Pubblicazione: (2020)
• Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
  di: Attili, Ilaria, et al.
  Pubblicazione: (2020)
• Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC—opportunities and obstacles
  di: Parris, Brielle A., et al.
  Pubblicazione: (2021)
• The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
  di: Lin, Chutong, et al.
  Pubblicazione: (2021)
• Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
  di: Arulananda, Surein, et al.
  Pubblicazione: (2020)